These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19170302)

  • 121. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).
    Wicks P; Massagli M; Kulkarni A; Dastani H
    J Med Internet Res; 2011 Jan; 13(1):e12. PubMed ID: 21266318
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
    Portaccio E; Amato MP
    CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
    [TBL] [Abstract][Full Text] [Related]  

  • 123. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
    Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
    Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 127. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
    Freedman SM; Cox D; Rosebrough T
    J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
    [TBL] [Abstract][Full Text] [Related]  

  • 128. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
    Sumino R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
    [No Abstract]   [Full Text] [Related]  

  • 129. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
    Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
    Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
    [TBL] [Abstract][Full Text] [Related]  

  • 130. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Interferon-beta injection site reactions in patients with multiple sclerosis.
    Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
    J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
    [TBL] [Abstract][Full Text] [Related]  

  • 132. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
    Lugaresi A
    Expert Opin Drug Deliv; 2013 Feb; 10(2):273-83. PubMed ID: 23252744
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 134. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 135.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 136.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 137.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 138.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 139.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 140.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.